Lytix Biopharma: A Quick Route to Market Prioritised - Redeye

Redeye provides an updated take on Lytix’ investment case. It assesses Lytix Biopharma's strategy to bring ruxotemitide to market as quickly as possible by moving directly into a registrational phase III trial after the ongoing NeoLIPA study.

Länk till analysen i sin helhet: https://www.redeye.se/research/1185770/lytix-biopharma-a-quick-route-to-market-takes-priority?utm_source=finwire&utm_medium=RSS